Gary Kohanbash

Title: Gary Kohanbash: Innovator in Tumor Immunotherapy

Introduction

Gary Kohanbash is a prominent inventor based in Pittsburgh, PA (US). He has made significant contributions to the field of cancer immunotherapy through his innovative research and patented technologies. His work focuses on the use of Th1-associated microRNAs for treating tumors, showcasing the potential of genetic approaches in cancer treatment.

Latest Patents

Gary Kohanbash holds a patent titled "Th1-associated microRNAs and their use for tumor immunotherapy." This patent describes the identification of microRNAs (miRNAs) that are up-regulated in Th1 cells compared to Th2 cells, specifically highlighting the miR-17-92 gene cluster. The findings indicate that over-expression of miR-17-92 in T cells promotes the Th1 phenotype, which can be utilized for cancer immunotherapy. The patent outlines methods for treating cancer by administering isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR-17-92 gene cluster.

Career Highlights

Gary Kohanbash is affiliated with the University of Pittsburgh, where he conducts his research and develops innovative solutions for cancer treatment. His work has garnered attention for its potential to improve therapeutic outcomes for cancer patients. With 1 patent to his name, he continues to push the boundaries of cancer immunotherapy.

Collaborations

Gary collaborates with esteemed colleagues, including Kotaro Sasaki and Hideho Okada. Their combined expertise enhances the research efforts and contributes to the advancement of cancer treatment methodologies.

Conclusion

Gary Kohanbash is a key figure in the field of tumor immunotherapy, with a focus on Th1-associated microRNAs. His innovative patent and collaborative efforts at the University of Pittsburgh highlight his commitment to advancing cancer treatment. His work represents a significant step forward in the fight against cancer.